600513.SHG Jiangsu Lianhuan Pharmaceutical Co Ltd
- Market cap
- CNY 3.77B
- P/E
- -
- P/B
- 2.86x
- ROE
- 1.3%
- Dividend yield
- 1.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 600513.SHG undervalued?
Graham numberThe Graham number of Jiangsu Lianhuan Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Lianhuan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Lianhuan Pharmaceutical Co Ltd yet.
Jiangsu Lianhuan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, dapoxetine hydrochloride, milrinone injection, aprilite, ebastine tablets, felodipine tablets, tadalafil, and betasine besylate tablets, as well as danazol suppositories, drapa…
Full company profileJiangsu Lianhuan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Lianhuan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 642M | 605M | 689M | 1.02B | 1.29B | 1.39B | 1.65B | 1.96B | 2.17B | 2.16B | 3.04B |
| Gross Profit | 366M | 354M | 475M | 699M | 775M | 745M | 897M | 1.04B | 1.04B | 1.06B | 904M |
| Operating Income | 58.9M | 76.6M | 90.4M | 88.6M | 102M | 143M | 156M | 187M | 175M | 131M | 95.7M |
| EBITDA | 87.9M | 105M | 119M | 115M | 131M | 182M | 209M | 257M | 258M | 215M | 78.5M |
| Net Income | 50.1M | 62.7M | 70.5M | 73.6M | 79.7M | 103M | 119M | 141M | 135M | 84.2M | 16.5M |
| EPS | 0.18 | 0.22 | 0.25 | 0.26 | 0.28 | 0.36 | 0.41 | 0.49 | 0.47 | 0.29 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.00B | 1.07B | 1.16B | 1.42B | 1.89B | 2.05B | 2.35B | 2.71B | 2.86B | 3.02B | 4.17B |
| Total Liabilities | 226M | 239M | 286M | 473M | 806M | 867M | 1.07B | 1.30B | 1.34B | 1.44B | 2.50B |
| Shareholders' Equity | 774M | 827M | 878M | 930M | 989M | 1.07B | 1.16B | 1.27B | 1.35B | 1.40B | 1.27B |
| Cash & Short-term Investments | 407M | 431M | 415M | 298M | 289M | 242M | 331M | 331M | 281M | 228M | 228M |
| Total Debt | 95.5M | 95.5M | 86.5M | 106M | 328M | 334M | 508M | 637M | 675M | 784M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 62.1M | 70.3M | 3.64M | -92.0M | -9.87M | 91.9M | 138M | 128M | 161M | 10.8M | - |
| Capital Expenditure | 27.4M | 46.2M | 48.6M | 128M | 169M | 174M | 169M | 209M | 201M | 185M | 183M |
| Free Cash Flow | 34.7M | 24.1M | -45.0M | -220M | -179M | -82.2M | -30.6M | -81.4M | -40.0M | -174M | -195M |
| Ratios | |||||||||||
| ROE | 6.5% | 7.6% | 8.0% | 7.9% | 8.1% | 9.6% | 10.3% | 11.2% | 10.0% | 6.0% | 1.3% |
| ROA | 5.0% | 5.9% | 6.1% | 5.2% | 4.2% | 5.0% | 5.0% | 5.2% | 4.7% | 2.8% | 0.4% |
| Net Profit Margin | 7.8% | 10.4% | 10.2% | 7.2% | 6.2% | 7.4% | 7.2% | 7.2% | 6.2% | 3.9% | 0.5% |
| Debt to Equity | 0.12x | 0.12x | 0.10x | 0.11x | 0.33x | 0.31x | 0.44x | 0.50x | 0.50x | 0.56x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Lianhuan Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.34%
- Forward dividend
- 0.07 CNY
- Payout ratio
- 60.1%
- Ex-dividend date
- Jul 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 50.6M | 0.17 | 60.1% |
| 2023 | CNY 43.1M | 0.15 | 31.9% |
| 2022 | CNY 54.4M | 0.19 | 38.5% |
| 2021 | CNY 31.1M | 0.11 | 26.2% |
| 2020 | CNY 42.5M | 0.15 | 41.3% |
| 2019 | CNY 22.3M | 0.08 | 27.9% |
| 2018 | CNY 27.8M | 0.10 | 37.8% |
| 2017 | CNY 23.0M | 0.08 | 32.6% |
| 2016 | CNY 14.8M | 0.05 | 23.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on May 19, 2017.
Who owns Jiangsu Lianhuan Pharmaceutical Co Ltd
- Insiders 42.38%
- Institutions 1.00%
- Public & others 56.61%
- Shares outstanding 285M
- Free float 208M
Jiangsu Lianhuan Pharmaceutical Co Ltd company profile
- Company name
- Jiangsu Lianhuan Pharmaceutical Co Ltd
- Ticker
- 600513.SHG
- ISIN
- CNE000001DP6
- Exchange
- Shanghai Stock Exchange
- Listed since
- Mar 4, 2003
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,131
- Fiscal year end
- December
- Address
- No. 9, Jiankang 1st Road, Yangzhou, China, 225127
- Phone
- 86 514 8277 8972
- Website
- lhpharma.com
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, dapoxetine hydrochloride, milrinone injection, aprilite, ebastine tablets, felodipine tablets, tadalafil, and betasine besylate tablets, as well as danazol suppositories, drapavelin hydrochloride injection, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules. In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, adapalene, milrinone, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, bilastine, crisaborole, argatroban, hexyl aminolevulinate hydrochloride, finerenone, enarodustat, dotinurad, methylprednisolone succinate, hydrocortisone sodium succinate, arotinolol hydrochloride, darlotamide, adapalene, triamcinolone acetonide acetate, baloxavir marboxil, acetoacetate methylprednisolone, vericiguat, and pemafibrate. Further, it engages in the wholesale of chemical raw materials and pharmaceuticals, as well as the sale of medical equipment and electronic products. The company exports its products. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is based in Yangzhou, China.
Jiangsu Lianhuan Pharmaceutical Co Ltd management
10- Mr. Zhen Hua QianChairman & Secretary of the Board · born 1971
- Mr. Ben NiuGM & Director · born 1981
- Mr. Hao XueFinancial Director · born 1990
- Mr. Liang Sheng ZhouChief Engineer · born 1970
- Mr. Qing Song ChuDeputy General Manager · born 1971
- Mr. Yi ShenDeputy General Manager · born 1966
- Mr. Zhang Kun HuDeputy General Manager · born 1971
- Ting Ting MaAccounting Supervisor
- Mr. Zhou JunDeputy General Manager · born 1970
- Mr. Yong Jun ZhuDeputy General Manager · born 1968